Today's CAR-T means taking a patient's immune cells out, engineering them in a lab for weeks, and putting them back. In-body CAR-T aims to do the same job with one injection, so the body makes the cancer-fighting cells itself.
First small human studies (Phase 1). Not approved anywhere. Only available inside clinical trials.
Your immune system has soldier cells called T-cells. Normally they cannot "see" some cancers. CAR-T gives them new instructions, a kind of homing device, so they can find and kill cancer cells. In-body CAR-T delivers those instructions straight into the bloodstream, wrapped in a tiny carrier that looks for T-cells.
Gene transfer happens in vivo. Current clinical candidates mostly use T-cell-targeted lentiviral vectors (e.g. CD3- or CD8-directed envelopes), which integrate the CAR permanently. Others use lipid nanoparticles carrying mRNA, which give temporary expression. Both early myeloma programmes below target BCMA.
Removing apheresis, ex vivo manufacture and (in some protocols) lymphodepletion is the core value proposition. In the KLN-1010 study investigators reported CAR-T expansion without lymphodepleting chemotherapy. The trade-off: dose, transduction efficiency and off-target transduction are controlled far less precisely than with a released, characterised cell product.
Phase 1, NCT06791681. Lentiviral, BCMA-directed. 3 stringent CRs by day 60; all patients had grade ≥3 AEs; one grade 1 ICANS; no DLTs reported. Nature Medicine, 2026.
Phase 1 inMMyCAR (planned n=20). Third-generation lentiviral vector with modified VSV-G fusogen and anti-CD3 targeting. MRD negativity at 10⁻⁶ in 3 patients, 10⁻⁵ in 1. CRS grade 1–2; no ICANS; one transient grade 4 neutropenia. ASH 2025.
Regulatory angle: integrating vectors bring long-term follow-up expectations (FDA guidance recommends up to 15 years for integrating gene therapy products), and in-body CAR-T is regulated as a gene therapy rather than a cell product. That shifts the CMC burden from cell manufacturing to vector manufacturing and changes how potency is defined.
Since 2025, several of the world's largest drug companies have paid billions of dollars to buy small companies working on in-body CAR-T.
| Company | Acquired / deal | Carrier type |
|---|---|---|
| Eli Lilly | Bought Kelonia, $7B (Apr 2026) | Lentiviral |
| AbbVie | Bought Capstan, $2.1B | LNP · mRNA |
| Bristol Myers Squibb | Bought Orbital, $1.5B (late 2025) | RNA |
| AstraZeneca | Bought EsoBiotec, up to $1B | Lentiviral |
| Gilead / Kite | Bought Interius, $350M (Aug 2025) | Lentiviral |
Not yet as a standard treatment. It is only available to people taking part in a clinical trial. If you are interested, ask your specialist and look up trials on ClinicalTrials.gov or the UK's ISRCTN registry. Be wary of any clinic offering it for a fee.
The idea is simple and powerful: let the body be the factory. The early numbers are striking, but nine patients prove the concept, not the treatment. The real test is whether larger trials can show it is safe and controllable.Draft opinion, to be rewritten in your own voice